Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | CASP1 | P29466 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | CASP7 | P55210 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | GRM5 | P41594 | 1/20 | 0.35 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.35 |
| ▸ | NR2E1 | Q9Y466 | 1/20 | 0.35 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.34 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL38651508 | 0.82 | NPC1 (0.44) | MEN1ALDH1A1KMT2ANPC1RAB9A | |
| SCHEMBL27380792 | 0.82 | NPC1 (0.44) | MEN1ALDH1A1KMT2ANPC1RAB9A | |
| SCHEMBL17151672 | 0.79 | KMT2A (0.42) | MAPTALDH1A1KMT2ANPC1RAB9A | |
| SCHEMBL29614831 | 0.79 | NR2E1 (0.55) | MAPTCASP1KDM4EMEN1ALDH1A1 | |
| SCHEMBL38651631 | 0.79 | MLLT3 (0.48) | MEN1ALDH1A1KMT2ANPC1RAB9A | |
| SCHEMBL3778638 | 0.79 | FAAH (0.40) | NPC1RAB9ANLRP3GRM5KDM2B | |
| SCHEMBL6803732 | 0.79 | NR2E1 (0.55) | MAPTCASP1KDM4EMEN1ALDH1A1 | |
| SCHEMBL27380503 | 0.79 | MLLT3 (0.48) | MEN1ALDH1A1KMT2ANPC1RAB9A | |
| SCHEMBL22466033 | 0.78 | MAPT (0.46) | MAPTKDM4EMEN1ALDH1A1ALOX15 | |
| SCHEMBL3782241 | 0.78 | NPC1 (0.51) | ALDH1A1NPC1RAB9ANLRP3GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7858649-B2 | Imidazole derivatives and their use for modulating the GABAA receptor complex | NEUROSEARCH A/S (DK) | 2010-12-28 | — | — | US | disclosed |
| US-7858649-B2 | Imidazole derivatives and their use for modulating the GABAA receptor complex | NEUROSEARCH A/S (DK) | 2010-12-28 | — | — | US | disclosed |
| US-7858649-B2 | Imidazole derivatives and their use for modulating the GABAA receptor complex | NEUROSEARCH A/S (DK) | 2010-12-28 | — | — | US | disclosed |
| US-20090163566-A1 | Imidazole Derivatives and their use for Modulating the Gabaa Receptor Complex | NEUROSEARCH A/S (DE) | 2009-06-25 | — | — | US | disclosed |
| US-20090163566-A1 | Imidazole Derivatives and their use for Modulating the Gabaa Receptor Complex | NEUROSEARCH A/S (DE) | 2009-06-25 | — | — | US | disclosed |
| US-20090163566-A1 | Imidazole Derivatives and their use for Modulating the Gabaa Receptor Complex | NEUROSEARCH A/S (DE) | 2009-06-25 | — | — | US | disclosed |
| US-20080312303-A1 | Imidazole Derivatives and Their Use for Modulating the Gabaa Receptor Complex | NEUROSEARCH A/S (DK) | 2008-12-18 | — | — | US | disclosed |
| US-20080312303-A1 | Imidazole Derivatives and Their Use for Modulating the Gabaa Receptor Complex | NEUROSEARCH A/S (DK) | 2008-12-18 | — | — | US | disclosed |
| US-20080312303-A1 | Imidazole Derivatives and Their Use for Modulating the Gabaa Receptor Complex | NEUROSEARCH A/S (DK) | 2008-12-18 | — | — | US | disclosed |
| EP-1940801-A2 | IMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABA-A RECEPTOR COMPLEX | NeuroSearch A/S (DK) | 2008-07-09 | — | — | EP | disclosed |
| EP-1940829-A2 | IMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABAA RECEPTOR COMPLEX | NeuroSearch A/S (DK) | 2008-07-09 | — | — | EP | disclosed |
| WO-2007042544-A2 | IMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABAA RECEPTOR COMPLEX | NEUROSEARCH A/S (DK) | 2007-04-19 | — | — | WO | disclosed |
| WO-2007042543-A2 | IMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABA-A RECEPTOR COMPLEX | NEUROSEARCH A/S (DK) | 2007-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163566-A1 | Imidazole Derivatives and their use for Modulating the Gabaa Receptor Complex | GABRB2, GABRB1, GABRB3 | MAPT 1150/4885CASP1 3514/4885KDM4E 3121/4885 |
| US-20080312303-A1 | Imidazole Derivatives and Their Use for Modulating the Gabaa Receptor Complex | GABRB2, GABRB1, GABRB3 | MAPT 820/4885CASP1 3024/4885KDM4E 2511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.